Earnings
Latvia’s Olainfarm has set out details of a five-year strategy called ‘Forward 2020-2025’ that it anticipates will “make internal processes more effective for sustainable growth.” While laying out its forecast for 2021, the company said that it has planned “significant investments for research and development, as well as the acquisition of products and modernization and digitalization.”
Japanese generics giant Sawai appears to be turning a corner, but the impact of National Health Insurance pricing revisions continues to hold the firm – and the rest of the country’s generics industry – back.
While Celltrion has delivered an unimpressive first quarter of 2021, the company has pointed to plans to launch high-margin products in new markets. The Korean firm said that it was looking to launch its subcutaneous Remsima SC infliximab formulation in Canada and Australia in 2021, while it is also aiming to launch its Yuflyma (adalimumab) in more than 70% of the EU adalimumab market.
After partnering with companies like Purna Female Healthcare and AFT Pharmaceuticals, Belgian value-added medicines specialist Hyloris has announced plans to add three new products to its pipeline in the coming months with a goal of having 14 commercial products by 2024.
Bangladesh’s Beximco reported double-digit growth both domestically and abroad in its financial first half, while continuing to expand in other international markets. Given its new launches and a COVID-19 vaccine distribution deal, the company remains optimistic about its future performance.
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.
The Citeline News & Insights Awards 2025 are now open for entries, inviting organizations, teams, and individuals from across the global life sciences sector to showcase their achievements and innovations. This year’s awards promise to be bigger and more inclusive than ever.
Facing a todo list top-heavy with critical, complex tasks, adults with ADHD often tackle the easier items — ones that keep them busy but not productive. Called “procrastivity,” this self-defeating ADHD time-management habit can be helped by CBT approaches that teach patients how to prioritize tasks.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
This character description generator will generate a fairly random description of a belonging to a random race. However, some aspects of the descriptions will remain the same, this is done to keep the general structure the same, while still randomizing the important details. The generator does take into account which race is randomly picked, and changes some of the details accordingly. For example, if the character is an elf, they will have a higher chance of looking good and clean, they will, of course, have an elvish name, and tend to be related to more elvish related towns and people. I've made the descriptions as detailed as possible, while also withholding as many details as possible. This may sound odd, but I've done it by mostly describing how a character looks, rather than his or her personality. I've tried to make the character's looks and some vague personality traits dictate what kind of person he or she could be.
Polpharma has struck a deal with MSN Laboratories that will see the Polish generics player distribute the Indian firm’s hospital portfolio in Poland.
Following the FDA’s approval of A 150mg version of Accord’ Herceptin biosimilar, the US agency has now greenlit a higher 400mg strength version of the rival.
Stada delivered solid growth in the first half of 2024, with complex generics launches and an increasingly prominent biosimilars business enabling two of its three operating divisions to report double-digit sales increases. Meanwhile, management also addressed persistent rumors of a possible sale by Stada’s owners.
Momentum in Europe may see the region’s contribution to Glenmark’s revenues become almost as big as the US business, currently dented by multiple challenges. The firm also outlines how things are poised in India for its biosimilar to Novo Nordisk’s Victoza.
Driven by increased orders, Alvotech is bullish on its US adalimumab biosimilar moving into 2025, as it also look forward to the US launch for its Stelara biosimilar early next year.
After a transformative last fiscal year, Sawai presented its financial first quarter results for its 2025 year, with slight disappointment among analysts due to missed revenue forecasts.
Despite reporting lower revenues in the first half of the year, Formycon continues to see value in its biosimilar projects, with a new candidate to be launched in the second half of 2024.